/Content/Upload/Product/Human_ELISA_kits_Diagnocine_1200_1200(453).jpg

Human Tumor necrosis factor receptor superfamily member 13B(TNFRSF13B) ELISA kit

Product#: CS-CSB-EL023971HU
$730.80
Availability:
Ships in 24 hours

The Ultimate 1-Stop ELISA Marketplace:

60,000+ ELISA kits Available to Serve Scientists from All Fields of Life Science

Always Powered by Diagnocine for Precision Research.

 
Made In-USA · ISO 13485 Certified 

Most comprehensive buffers, reagents and detection agents are provided with each kit to optimize data output.  
All-inclusive format covers everything from sample preparation to signal detection.  Every step can be customized and optimized for your precision research.
DiagnoCine Precision buffers and reagents are Made in USA ISO 13485 Certified

One Stop Purchasing but Zero Compromise on Accuracy

Why waste time searching for your ELISA kit when you can get everything in one place? Diagnocine can provide you with all the ELISA needs you have (customized ELISAs also available) on the planet through a single, streamlined ordering process.  
* all types of species
* HRP and AP detection
* Low target signal enhancement
* Inquire about a trial version or a customized version

Low Signal Optimization Reagents

4 core reagents below are included with every order, plus 1 of the 2 detection-specific reagents (matched automatically to your kit type) — 5 components, every time.

DCP-PIC100X

Protease Inhibitor Cocktail (100X)

Included with every order
 DCP-SM1AbTBS1X

SigMax 1Ab-TBS

Included with every order
 DCP-UTBS1X

Universal Blocking Buffer

Included with every order
 DCP-SM2AbTBS1X

SigMax 2Ab-TBS

Included with every order

+ the 5th component, matched to your kit's detection method:

DCP-HRPTBS1X

HRPQuench-TBS

Exclusively for HRP-based kits
OR
DCP-ALPTBS1X

ALPQuench-TBS

Exclusively for ALP-based kits

If you have any questions or need additional information, please call us at 551-245-1033 or email us at support@diagnocine.com. Our team will be happy to assist you.

Key Value Highlights

Universal Compatibility

All buffers and detection reagents work seamlessly across target proteins, bridging the gap in assay consistency.

1-Stop Convenience

Consolidate your lab's purchasing. Source all ELISA needs and experience optimal buffers and reagents in a single shipment.

Enhanced Precision

Designed by scientists for scientists,  all components are engineered to deliver sharper results and an optical signal.

Human ELISA Kit · Immunology

Human Tumor necrosis factor receptor superfamily member 13B(TNFRSF13B) ELISA kit

Sandwich quantitative immunoassay for Human Tumor necrosis factor receptor superfamily member 13B(TNFRSF13B) ELISA kit in human serum, plasma, tissue homogenates  available in multiple catalog sizes:

Trial 24T 96T

Note: Please send inquiries regarding Trial 24T orders to support@diagnocine.com.

Detection Range
78-5,000 pg/ml
Sensitivity
19.5 pg/ml
Assay Time
1-5 hours
Sample Volume
50-100 μL
Product specifications
Uniprot No.O14836
SpeciesHomo sapiens (Human)
Sample typesserum, plasma, tissue homogenates
Detection range78 pg/ml - 5000 pg/ml
Sensitivity19.5 pg/ml
Assay time1-5h
Sample loading volume50-100μL
Detection wavelength450 nm
Assay principleSandwich (Quantitative)
Data analysisStandard curve + Curve Expert software
Research areaImmunology
Storage condition2-8°C (see protocol for full details)
Shipping condition4 °C
Shelf life6 months
Human Tumor necrosis factor receptor superfamily member 13B(TNFRSF13B) ELISA kit serum plasma tissue homogenates Immunology Human ELISA
Lead Time

10 business days

Processing + 3-5 days shipping

Availability

In Stock : USA

Worldwide shipping available

Assay principle
Sample prep
Antibody capture
450 nm detection
Standard curve
Quantification

In this sandwich ELISA, Human Tumor necrosis factor receptor superfamily member 13B(TNFRSF13B) ELISA kit in the sample is captured between a pre-coated capture antibody and a detection antibody. Signal intensity is proportional to analyte concentration. Quantification uses a standard curve fitted with Curve Expert software, covering 78 pg/ml - 5000 pg/ml with a minimum detectable dose of 19.5 pg/ml.

For research use only (RUO). Not intended for diagnostic or therapeutic purposes. Validated in human serum, plasma, tissue homogenates matrices only.
Alternative Names
TNFRSF13B; TACI; Tumor necrosis factor receptor superfamily member 13B; Transmembrane activator and CAML interactor; CD antigen CD267
Function
Receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. Involved in the stimulation of B- and T-cell function and the regulation of humoral immunity.
Gene References into Functions
  1. Expression of BCMA, TACI, and BAFF-R by multiple myeloma cells support cell growth and survival. PMID: 14512299
  2. TACI(hi) myeloma cells displayed a mature plasma cell gene signature, indicating dependence on the BM environment. In contrast, the TACI(lo) group had a gene signature of plasmablasts, suggesting an attenuated dependence on the BM environment PMID: 15827134
  3. 4 of 19 unrelated individuals with common variable immunodeficiency and 1 of 16 individuals with IgA deficiency had a missense mutation in one allele of TNFRSF13B PMID: 16007086
  4. identified homozygous and heterozygous mutations in TNFRSF13B, encoding TACI, in 13 individuals with common variable immunodeficiency PMID: 16007087
  5. Review. Short-lived antibody forming cell populations and their proliferating progenitors express a TACI-predominant signature. PMID: 16919470
  6. The TACI inhibited HRS cell accumulation in vitro and might attenuate HL expansion in vivo. PMID: 16960154
  7. simultaneous binding of TACI and HSPG on B cells with APRIL is crucial for IgA production PMID: 17119122
  8. TACI-specific signaling inhibits both B cell activating factor of the TNF family receptor (BAFF-R) and CD40-enhanced antibody production from peripheral blood B cells in vitro, although TACI-specific signaling directly induces mild B cell apoptosis. PMID: 17154264
  9. This review defines the exact contribution of TACI receptor stimulation by specific triggers in vitro, enabling us to better understand the complex, context-dependent responses initiated by TACI in vivo. PMID: 17171762
  10. Role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. PMID: 17392797
  11. novel mutations identified in this study support the notion of a crucial role for TACI in B cell differentiation PMID: 19629655
  12. the TNFRSF13B A181E mutation is associated with a very heterogeneous clinical presentation along with variability in B-cell numbers and amount of TACI protein on memory B cells in Common Variable ImmunoDeficiency PMID: 20156508
  13. MyD88 controls a B cell-intrinsic, TIR-independent, TACI-dependent pathway for immunoglobulin diversification PMID: 20676093
  14. mutations result in impaired B cell response through haploinsufficiency PMID: 20889194
  15. TACI expression on CD19+ B cells was up-regulated in patients with lupus nephritis PMID: 20974656
  16. We have examined the function of TACI coding variants that have been described in patients with common variable immunodeficiency PMID: 21419480
  17. In patients with Smith-Magenis syndrome with only 1 TACI allele, we found decreased B-cell expression of TACI, reduced binding of a proliferation-inducing ligand, and decreased TACI-induced expression of activation-induced cytidine deaminase mRNA. PMID: 21514638
  18. Our data provide further evidence that TNFRSF13B/TACI alterations are not causative of common variable immunodeficiency PMID: 21547394
  19. primary leukemia B-cell precursors aberrantly express receptors of the BAFF-system, BAFF-R, BCMA, and TACI PMID: 21687682
  20. Signals from TLR9, TACI, and CD40 are integrated to promote B-cell activation and differentiation. PMID: 21741080
  21. We conclude that mutations in TACI are the contributing factors for asthma symptoms in Swedish children, although the mechanisms still remain elusive. PMID: 21850030
  22. the identification of two novel mutations in TNFRSF13B, including one, S231R, affecting the highly conserved THC domain PMID: 22076597
  23. Two pediatric Italian male siblings were affected with hypogammaglobulinemia and recurrent respiratory and gastrointestinal infections in association with a novel compound heterozygous I87N/C104R TACI mutation. PMID: 22627058
  24. Three SNPs located in TNFRSF13B on 17p11.2 or nearby were significantly associated with IgG level. PMID: 22673310
  25. Data suggest a different impact of TACI mutations, from hypogammaglobulinemia in children to autoimmune disease in adulthood. PMID: 22697072
  26. A significant association of TNFRSF13B gene mutations was observed in common variable immunodeficiency patients. PMID: 22884984
  27. Segregation analysis of a kindred shows that inheriting single or double copy of the Cys104Arg mutation does not necessarily consign an individual to common variable immunodeficiency (CVID). PMID: 22983507
  28. Naturally occurring mutation affecting the MyD88-binding site of TNFRSF13B impairs triggering of class switch recombination. PMID: 23225259
  29. Intracellular and extracellular TACI expression was defective for B cells of all subjects with mutations. PMID: 23237420
  30. genetic polymorphism is associated with lung function in Hutterites, who are a founder population of European descent in North America PMID: 23932459
  31. TNFRSF13B/TACI defects alone do not result in CVID but may be also found frequently in distinct clinical phenotypes, including benign lymphoproliferation and IgG subclass deficiencies. PMID: 23956760
  32. TACI mutations enables autoimmune complications in common variable immune deficiency . PMID: 24051380
  33. In conclusion, we confirmed the prognostic significance of soluble BLyS levels with regard to TFT in CLL patients, and, more importantly, we showed for the first time that sTACI is a powerful prognostic marker, related to parameters of disease activity PMID: 25162001
  34. Data show significant differences in expression of tumour necrosis factor family (BAFF) receptors BAFF-R, BCMA and TACI in patients with and without anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. PMID: 25301447
  35. The released sTACI is an immunoregulator that shares decoy functions with atacicept. It reflects systemic and compartmentalized B cell accumulation and activation. PMID: 25505277
  36. serum levels not associated with disease activity in MPO-ANCA-associated renal vasculitis PMID: 25567522
  37. Although the transcriptional controls for alternative splicing of TACI isoforms remain unknown, differential signals via isoforms may control plasma-cell generation. PMID: 25631768
  38. only Transmembrane Activator and CAML Interactor (TACI) correlates with the MMC's capability to ligate BAFF. Additionally, the level of expression of TACI correlates with the level of the MMC's BM dependency PMID: 25723853
  39. Common variable immune deficiency patients with heterozygous mutations in TACI alleles increase susceptibility to autoimmune diseases. PMID: 25866827
  40. The study demonstrated that there is a remarkable interindividual variability of TACI expression in chronic lymphocytic leukemia, although the majority of patients display low to undetectable TACI. PMID: 25950010
  41. In this review, we aim at giving an insight into the genetics underlying the CVID and particularly at outlining the role of TACI and its relative contribution to the development of CVID-like phenotypes in human. PMID: 26096648
  42. TNFRSF13B hemizygosity does not recapitulate autoimmune features of common variable immune deficiency -associated C104R and A181E TNFRSF13B mutations, which likely encode dominant negative products, but instead reveals selective TACI haploinsufficiency at later stages of B-cell development. PMID: 26100089
  43. Variants of TNFRSF13B were associated with common variable immunodeficiency. PMID: 26122175
  44. genetic polymorphism is associated with hypogammaglobulinemia and systemic lupus erythematosis in a family with common variable immunodeficiency disorder PMID: 26623716
  45. C104R mutation was associated with common variable immunodeficiency and IgG subclass deficiency. PMID: 26727773
  46. 11% of common variable immunodeficiency patients and 13% of antibody deficiency syndromes patients carried at least one mutated TNFRSF13B allele. PMID: 27123465
  47. results suggest that TACI A181E heterozygosity results in TACI haploinsufficiency with increased susceptibility to pneumococcal infection PMID: 27609654
  48. BAFF-induced processing of BAFFR regulates BAFF-mediated B cell responses in a TACI-dependent manner. PMID: 28249164
  49. p.G76S gain-of-function mutation on the TNFRSF13B gene is responsible for familial or sporadic immune thrombocytopenia. PMID: 28834165
  50. Expression patterns of BAFF and its receptor TACI differ according to lupus nephritis class. PMID: 29087261
Involvement in disease
Immunodeficiency, common variable, 2 (CVID2); Immunoglobulin A deficiency 2 (IGAD2)
Tissue Specificity
Highly expressed in spleen, thymus, small intestine and peripheral blood leukocytes. Expressed in resting B-cells and activated T-cells, but not in resting T-cells.
Subcellular Location
Membrane; Single-pass type III membrane protein.
Database Links

HGNC: 18153

OMIM: 240500

KEGG: hsa:23495

STRING: 9606.ENSP00000261652

UniGene: Hs.158341

Satisfaction
Quality Rating
Value Rating
Style Rating
X